Depreciation of Allogene Therapeutics, Inc. from 31 Dec 2017 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Allogene Therapeutics, Inc. quarterly and annual Depreciation in USD history and change rate from 31 Dec 2017 to 31 Mar 2024.
  • Allogene Therapeutics, Inc. Depreciation for the quarter ending 31 Mar 2024 was $3,555,000, a 1.4% increase year-over-year.
  • Allogene Therapeutics, Inc. annual Depreciation for 2023 was $14,199,000, a 0.67% decline from 2022.
  • Allogene Therapeutics, Inc. annual Depreciation for 2022 was $14,295,000, a 37% increase from 2021.
  • Allogene Therapeutics, Inc. annual Depreciation for 2021 was $10,454,000, a 41% increase from 2020.
Source SEC data
View on sec.gov
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

Allogene Therapeutics, Inc. Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $3,555,000 +$48,000 +1.4% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2024 2024 Q1
Q1 2023 $3,507,000 -$185,000 -5% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q1 2022 $3,692,000 +$1,774,000 +92% 01 Jan 2022 31 Mar 2022 10-Q 03 May 2023 2023 Q1
Q1 2021 $1,918,000 +$25,000 +1.3% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q1 2020 $1,893,000 +$1,349,000 +248% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021 2021 Q1
Q1 2019 $544,000 01 Jan 2019 31 Mar 2019 10-Q 06 May 2020 2020 Q1
Q4 2017 $0 30 Nov 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY

Allogene Therapeutics, Inc. Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $14,199,000 -$96,000 -0.67% 01 Jan 2023 31 Dec 2023 10-K 14 Mar 2024 2023 FY
2022 $14,295,000 +$3,841,000 +37% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
2021 $10,454,000 +$3,019,000 +41% 01 Jan 2021 31 Dec 2021 10-K 14 Mar 2024 2023 FY
2020 $7,435,000 +$3,011,000 +68% 01 Jan 2020 31 Dec 2020 10-K/A 14 Mar 2024 2022 FY
2019 $4,424,000 +$3,376,000 +322% 01 Jan 2019 31 Dec 2019 10-K 23 Feb 2022 2021 FY
2018 $1,048,000 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.